K. Kalbakis

886 total citations
37 papers, 727 citations indexed

About

K. Kalbakis is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, K. Kalbakis has authored 37 papers receiving a total of 727 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 11 papers in Cancer Research. Recurrent topics in K. Kalbakis's work include Cancer Treatment and Pharmacology (22 papers), Lung Cancer Treatments and Mutations (9 papers) and Colorectal Cancer Treatments and Studies (8 papers). K. Kalbakis is often cited by papers focused on Cancer Treatment and Pharmacology (22 papers), Lung Cancer Treatments and Mutations (9 papers) and Colorectal Cancer Treatments and Studies (8 papers). K. Kalbakis collaborates with scholars based in Greece, United States and Netherlands. K. Kalbakis's co-authors include Sofia Agelaki, Dimitriοs Mavroudis, D. Mavroudis, S. Kakolyris, John Souglakos, Ch. Kouroussis, V. Georgoulias, Stylianos Kakolyris, Alexandros Xyrafas and Maria Perraki and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and British Journal of Cancer.

In The Last Decade

K. Kalbakis

35 papers receiving 707 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
K. Kalbakis Greece	17	544	242	234	122	101	37	727
Emi Noguchi Japan	12	352 0.6×	120 0.5×	208 0.9×	115 0.9×	51 0.5×	63	608
Alberto Laffranchi Italy	11	630 1.2×	269 1.1×	156 0.7×	69 0.6×	46 0.5×	22	829
Rubina Qamar United States	12	479 0.9×	210 0.9×	239 1.0×	203 1.7×	58 0.6×	21	908
Pavlos Papakotoulas Greece	16	777 1.4×	292 1.2×	426 1.8×	144 1.2×	109 1.1×	52	1.0k
U. Klaassen Germany	14	642 1.2×	203 0.8×	130 0.6×	115 0.9×	78 0.8×	31	777
E. Sandberg Denmark	10	382 0.7×	170 0.7×	163 0.7×	60 0.5×	221 2.2×	17	749
N. Vardakis Greece	17	629 1.2×	65 0.3×	416 1.8×	163 1.3×	94 0.9×	33	762
Mauro D’Amico Italy	10	1.0k 1.9×	286 1.2×	414 1.8×	155 1.3×	185 1.8×	32	1.2k
Joan Sorich United States	13	439 0.8×	63 0.3×	97 0.4×	330 2.7×	203 2.0×	31	759
Tarek Chidiac United States	11	802 1.5×	128 0.5×	384 1.6×	207 1.7×	102 1.0×	16	1.0k

Countries citing papers authored by K. Kalbakis

Since Specialization

Citations

This map shows the geographic impact of K. Kalbakis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Kalbakis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Kalbakis more than expected).

Fields of papers citing papers by K. Kalbakis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Kalbakis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Kalbakis. The network helps show where K. Kalbakis may publish in the future.

Co-authorship network of co-authors of K. Kalbakis

This figure shows the co-authorship network connecting the top 25 collaborators of K. Kalbakis. A scholar is included among the top collaborators of K. Kalbakis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Kalbakis. K. Kalbakis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rounis, Konstantinos, Dimitrios Makrakis, Nikolaos Galanakis, et al.. (2021). Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study. Translational Lung Cancer Research. 10(8). 3538–3549. 38 indexed citations

Matikas, Alexios, Αthanasios Kotsakis, Maria Perraki, et al.. (2021). Objective Response to First-Line Treatment as a Predictor of Overall Survival in Metastatic Breast Cancer: A Retrospective Analysis from Two Centers over a 25-Year Period. Breast Care. 17(3). 264–271. 4 indexed citations

Rounis, Konstantinos, Dimitrios Makrakis, Chara Papadaki, et al.. (2021). Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study. PLoS ONE. 16(6). e0252537–e0252537. 23 indexed citations

Agelaki, Sofia, et al.. (2020). 299P MicroRNAs related to immune response as markers in the prognosis of metastatic breast cancer. Annals of Oncology. 31. S362–S362. 1 indexed citations

Apostolou, Paraskevi, Florentia Fostira, Charalambos Kouroussis, et al.. (2020). BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects. International Journal of Cancer. 147(5). 1334–1342. 8 indexed citations

Mavroudis, Dimitriοs, Emmanouil Saloustros, Ioannis Boukovinas, et al.. (2017). Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group. British Journal of Cancer. 117(2). 164–170. 8 indexed citations

Saloustros, Emmanouil, Michail Nikolaou, K. Kalbakis, et al.. (2017). Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group. Clinical Breast Cancer. 18(1). 88–94. 17 indexed citations

Karachaliou, Niki, Ch. Kouroussis, Pavlos Papakotoulas, et al.. (2012). A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer. Cancer Chemotherapy and Pharmacology. 69(5). 1345–1352. 2 indexed citations

Georgoulias, Vasilis, V. Bozionelou, Sofia Agelaki, et al.. (2012). Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study. Annals of Oncology. 23(7). 1744–1750. 118 indexed citations

10.

Bree, Eelco de, Hilde Rosing, John Romanos, et al.. (2008). Cytoreductive Surgery and Intraoperative Hyperthermic Intraperitoneal Chemotherapy with Paclitaxel: A Clinical and Pharmacokinetic Study. Annals of Surgical Oncology. 15(4). 1183–1192. 57 indexed citations

11.

Kakolyris, Stylianos, K. Kalbakis, Anna Potamianou, et al.. (2006). Salvage Chemotherapy with Gemcitabine and Oxaliplatin in Heavily Pretreated Patients with Metastatic Breast Cancer: A Multicenter Phase II Study. Oncology. 70(4). 273–279. 6 indexed citations

12.

Kouroussis, Charalambos, Dimitris Mavroudis, Stylianos Kakolyris, et al.. (2004). High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study. Lung Cancer. 44(3). 363–368. 56 indexed citations

13.

Mavroudis, D., Nikolaos Malamos, Aris Polyzos, et al.. (2004). Front-Line Chemotherapy with Docetaxel and Gemcitabine Administered Every Two Weeks in Patients with Metastatic Breast Cancer: A Multicenter Phase II Study. Oncology. 67(3-4). 250–256. 24 indexed citations

14.

Souglakos, John, Nikolaos Androulakis, Dimitriοs Mavroudis, et al.. (2003). Multicenter dose-finding study of concurrent capecitabine and radiotherapy as adjuvant treatment for operable rectal cancer. International Journal of Radiation Oncology*Biology*Physics. 56(5). 1284–1287. 27 indexed citations

15.

Vamvakas, L., S. Kakolyris, Ch. Kouroussis, et al.. (2002). Irinotecan (CPT-11) in Combination With Infusional 5-Fluorouracil and Leucovorin (de Gramont Regimen) as First-Line Treatment in Patients With Advanced Colorectal Cancer. American Journal of Clinical Oncology. 25(1). 65–70. 16 indexed citations

16.

Mavroudis, D., Ch. Kouroussis, S. Kakolyris, et al.. (2002). Phase I Study of Paclitaxel (Taxol) and Pegylated Liposomal Doxorubicin (Caelyx) Administered Every 2 Weeks in Patients with Advanced Solid Tumors. Oncology. 62(3). 216–222. 29 indexed citations

17.

Kakolyris, S., Ch. Kouroussis, Michael I. Koukourakis, et al.. (2002). A Dose-Escalation Study of Oxaliplatin and Vinorelbine in Patients with Advanced Solid Tumors. Oncology. 63(3). 213–218. 6 indexed citations

18.

Agelaki, Sofia, A. Alexopoulos, Charalambos Kouroussis, et al.. (2001). Salvage treatment with irinotecan and gemcitabine in breast cancer patients pretreated with taxanes and anthracyclines: a multicenter phase II study. European Journal of Cancer. 37. S197–S198. 1 indexed citations

19.

Kouroussis, Ch., Sofia Agelaki, D. Mavroudis, et al.. (2000). A dose escalation study of weekly docetaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 46(6). 488–492. 21 indexed citations

20.

Mavroudis, Dimitriοs, A. Alexopoulos, Nikolaos Ziras, et al.. (2000). Front-line treatment of advanced breast cancer with docetaxel and epirubicin: A multicenter phase II study. Annals of Oncology. 11(10). 1249–1254. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact